## SOLV: Solventum Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.8% below STRENGTH zone (3.0-6.0%); PEG 1.41 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($77.61)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 0 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+5.3%)
- Independent Franchis: 7.4% (+27.2%)
- Blackrock Inc.: 5.9% (+6.1%)
- Trian Fund Managemen: 4.9% (0.0%)
- State Street Corpora: 3.6% (+1.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +2.3% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.41 suggests fair value with growth premium. Forward P/E 12.7x stretched relative to 6% growth. Quality metrics strong (ROE 37%, margin 18%). Institutional flow bullish (8 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.0B |
| Beta | 1.00 |
| 52W Range | $60.70 - $88.20 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.41 |
| Forward P/E | 12.7 |
| Current P/E | 13.4 |
| YoY Growth | 5.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.5% to 0.8% (+2.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.2pp (needs >3.0% for momentum thesis). MRS_5 at 1.0% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). RSI neutral at 52. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.76% (CS: 50) | Neutral |
| RSI_14 | 52.4 | Neutral |
| MACD Histogram | -0.42 | Bearish |
| vs SMA20 | 0.996x | Below |
| vs SMA50 | 1.035x | Above |
| vs SMA200 | 1.096x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $80.79
- **Stop Loss:** $77.61 (3.9% risk)
- **Target:** $83.97 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 271
- **Position Value:** $21,894.09
- **Portfolio %:** 21.89%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-26 (Est: $1.49)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.43 | $1.50 | +4.7% |
| 2025Q2 | $1.45 | $1.69 | +16.2% |
| 2025Q1 | $1.22 | $1.34 | +9.7% |
| 2024Q4 | $1.31 | $1.41 | +7.8% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_10*